< Back to situations

[ORGANIZATION]

Amgen

Featured in 3 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [US] [AU]

US biotech Q2 earnings reports

2 clusters · 12 sources · last updated

Latest: Amgen posts 9% Q2 sales growth and earnings beat as biotech peers report results

In late July 2026 Biogen posted a modest 3% year‑over‑year revenue rise to $2.7 billion, driven by its multiple‑sclerosis drugs and newer products such as Skyclarys and Leqembi. A week later Amgen reported stronger Q2 pe

[ACTIVE] [HEALTH] [US] [DE] [GB]

Eli Lilly retatrutide trials, access & market backdrop

2 clusters · 10 sources · last updated

Latest: Eli Lilly’s Mounjaro sales surge as GLP‑1 weight‑loss drugs spark market and safety debate

Late July 2026 topline data from Phase III TRIUMPH‑2 and TRIUMPH‑3 showed retatrutide induced up to 22.6 % weight loss in severely obese adults with cardiovascular disease, alongside improvements in glycaemic control, li

Also covered in